Stellenwert der ASS-Therapie in der kardio- und zerebrovaskulären Prävention

Zusammenfassung

Acetylsalicylsäure (ASS), eines der am meisten verwendeten Medikamente weltweit, spielt als Thrombozytenaggregationshemmer eine bedeutende Rolle bei der Behandlung und Sekundärprophylaxe vieler vaskulärer Erkrankungen. Dagegen ist die primärprophylaktische Indikation umstritten. Nach der neuesten Evidenz wird der Einsatz von ASS zunehmend kritisch bei Patienten ohne bestehende atherosklerotische Erkrankungen bewertet. Zwar senkt die Substanz die ischämischen Ereignisse, dies geht allerdings mit einem erhöhten Blutungsrisiko einher, sodass in der Summe kein relevanter klinischer Vorteil übrigbleibt. Deswegen wird das Mittel bei Patienten ohne nachgewiesene kardio- bzw. zerebrovaskuläre Erkrankung generell nicht empfohlen.

Abstract

Acetylsalicylic acid (aspirin) is one of the most used medications worldwide. The antithrombotic agent acts mainly through inhibition of cyclooxygenase-1 and consequently thromboxane A₂ synthesis, causing an irreversible suppression of platelet function. Despite of its proven benefit in the treatment and secondary prevention of atherosclerotic diseases, its use for the primary prevention remains controversial due to an unclear balance between the benefits and risks of aspirin. Moreover, the recent evidence indicates that the risk of major bleeding outweighs the potential to reduce ischemic events in patients without atherosclerotic diseases, thus, precluding the general use of aspirin for the primary prevention.

Schlüsselwörter

Acetylsalicylsäure - Prävention - Atherosklerose

Key words

acetylsalicylic acid - prevention - atherosklerosis

Publication History

Article published online:
13 October 2021

• Literatur

• 1 Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res 2014; 12: 147-154 DOI: 10.3121/cmr.2013.1197.
• 2 Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. Circulation 2011; 123: 768-778 DOI: 10.1161/CIRCULATIONAHA.110.963843.
• 3 Craven LL. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg 1950; 4: 95
• 4 Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971; 231: 235-237 DOI: 10.1038/newbio231235a0.
• 5 Chandrasekharan NV, Dai H, Roos KL. et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926-13931 DOI: 10.1073/pnas.162468699.
• 6 FitzGerald GA, Oates JA, Hawiger J. et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688 DOI: 10.1172/jci110814.
• 7 Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975; 56: 624-632 DOI: 10.1172/JCI108132.
• 8 Heavey DJ, Barrow SE, Hickling NE. et al. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man. Nature 1985; 318: 186-188 DOI: 10.1038/318186a0.
• 9 Steering Committee of the Physiciansʼ Health Study Research G. Final report on the aspirin component of the ongoing Physiciansʼ Health Study. N Engl J Med 1989; 321: 129-135 DOI: 10.1056/NEJM198907203210301.
• 10 McNeil JJ, Nelson MR, Woods RL. et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018; 379: 1519-1528 DOI: 10.1056/NEJMoa1803955.
• 11 Johnston SC, Easton JD, Farrant M. et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018; 379: 215-225 DOI: 10.1056/NEJMoa1800410.
• 12 Gaziano JM, Brotons C, Coppolecchia R. et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018; 392: 1036-1046 DOI: 10.1016/S0140-6736(18)31924-X.
• 13 Cosentino F, Grant PJ, Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41: 255-323 DOI: 10.1093/eurheartj/ehz486.
• 14 Group ASC, Bowman L, Mafham M. et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018; 379: 1529-1539 DOI: 10.1056/NEJMoa1804988.
• 15 Zheng SL, Roddick AJ. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis. JAMA 2019; 321: 277-287 DOI: 10.1001/jama.2018.20578.
• 16 Lewis HD, Davis Jr JW, Archibald DG. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403 DOI: 10.1056/NEJM198308183090703.
• 17 Cairns JA, Gent M, Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369-1375 DOI: 10.1056/NEJM198511283132201.
• 18 Theroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-1111 DOI: 10.1056/NEJM198810273191701.
• 19 Juul-Moller S, Edvardsson N, Jahnmatz B. et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340: 1421-1425 DOI: 10.1016/0140-6736(92)92619-q.
• 20 Patrono C, Coller B, Dalen JE. et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 1998; 114: 470S-488S DOI: 10.1378/chest.114.5_supplement.470s.
• 21 Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18: 1587-1593 DOI: 10.1016/0735-1097(91)90489-v.
• 22 Jones WS, Mulder H, Wruck LM. et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med 2021; DOI: 10.1056/NEJMoa2102137.
• 23 Sandercock PA, Counsell C, Tseng MC. et al. Oral antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2014; CD000029 DOI: 10.1002/14651858.CD000029.pub3.
• 24 Antithrombotic Trialists C, Baigent C, Blackwell L. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860 DOI: 10.1016/S0140-6736(09)60503-1.
• 25 Rothwell PM, Algra A, Chen Z. et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388: 365-375 DOI: 10.1016/S0140-6736(16)30468-8.
• 26 Hansson L, Zanchetti A, Carruthers SG. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762 DOI: 10.1016/s0140-6736(98)04311-6.
• 27 [Anonym]. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Councilʼs General Practice Research Framework. Lancet 1998; 351: 233-241
• 28 de Gaetano G. Collaborative Group of the Primary Prevention P. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95 DOI: 10.1016/s0140-6736(00)03539-x.
• 29 Cote R, Battista RN, Abrahamowicz M. et al. Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 1995; 123: 649-655 DOI: 10.7326/0003-4819-123-9-199511010-00002.
• 30 Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke 2009; 40: e573-e583 DOI: 10.1161/STROKEAHA.109.556068.
• 31 Halliday A, Harrison M, Hayter E. et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet 2010; 376: 1074-1084 DOI: 10.1016/S0140-6736(10)61197-X.
• 32 Patrono C, Garcia Rodriguez LA, Landolfi R. et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383 DOI: 10.1056/NEJMra052717.
• 33 Eckstein HH, Kuhnl A, Berkefeld J. et al. [Webinar for S3 guideline „diagnosis, treatment, and aftercare of extracranial carotid stenosis“]. Chirurg 2021; 92: 383-384 DOI: 10.1007/s00104-021-01393-x.
• 34 Judge C, Ruttledge S, Murphy R. et al. Aspirin for primary prevention of stroke in individuals without cardiovascular disease-A meta-analysis. Int J Stroke 2020; 15: 9-17 DOI: 10.1177/1747493019858780.
• 35 Sacco M, Pellegrini F, Roncaglioni MC. et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003; 26: 3264-3272 DOI: 10.2337/diacare.26.12.3264.
• 36 Ridker PM, Manson JE, Gaziano JM. et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-839 DOI: 10.7326/0003-4819-114-10-835.